drugset / Trial / NCT07410806

HEALEY ALS Platform Trial - Regimen I NUZ-001

NCT07410806

Phase 2/3 Active not recruiting 240 enrolled Merit E. Cudkowicz, MD Neurizon Therapeutics Limited · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen I will evaluate the safety and efficacy of a single study drug, NUZ-001, in participants with ALS.

Timeline

Start
2026-02-25
Primary completion
2027-07-01
Completion
2028-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject NUZ-001 Unknown Oral